Benzodiazepine Screen
Viruses Included in Panel
Organisms Included in Panel
Test Utility
This test is used to detect the presence of illicit or prescription medications in urine.
Urine Drug Screen Profile Includes:
Methodology
Immunoassay screen for qualitative detection of benzodiazepine in urine.
Benzodiazepines are sedative-hypnotic drugs, which are subject to abuse. Benzodiazepines are structurally similar and include a wide variety of drugs such as alprazolam, chlordiazepoxide, diazepam, lorazepam, oxazepam and triazolam. They are absorbed and metabolized at different rates, resulting in various psychoactive effects. Therefore, the detection of benzodiazepines or their metabolites in urine can be used as an indicator of benzodiazepine abuse.
The benzodiazepine screening assay uses a specific antibody which can detect most benzodiazepines and their metabolites in urine. The assay is based on the competition of an enzyme glucose 6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, the enzyme-labeled drug is bound by the specific antibody and the enzyme activity is inhibited. This phenomenon creates a relationship between drug concentration in urine and enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.
Methodology
Screen Test Name | Assay Type |
|---|---|
ETG
| DRI |
Amphetamine
| DRI |
Barbiturates
| DRI |
Benzodiazepine
| DRI |
Cotinine
| DRI
|
Cocaine
| DRI |
Methadone
| DRI |
Opiate
| DRI |
Oxycodone
| DRI |
THC
| DRI |
Fentanyl
| DRI |
Buprenorphine | CEDIA
|
PCP
| DRI |
Individual Test Information Including Methodology & Reference Ranges
Reflex to UTI Criteria
Specimen Collection and Preparation
At least 1 mL of urine should be collected in a urine specimen container.
Specimen Storage and Stability
Urine specimen should be stored under refrigerated conditions (2–8°C) until analysis. Samples will also be stored under refrigerated conditions on site for 2 weeks post analysis.
Specimen Rejection
Insufficient sample volume
Specimen labeled incorrectly or not labeled
Specimen validity tests indicate adulterated test
Reference Range (Cutoff)
Test results above the assay cutoff are reported as Positive.
Test results under the cutoff are reported as Negative.
If the reflex from the positive screen is ordered, the following confirmation analytes will be tested via LC/MS/MS:
α-Hydroxyalprazolam
α-Hydroxytriazolam
2-Hydroxyethylflurazepam
Alprazolam
7-Aminoclonazepam
Chlordiazepoxide
Clonazepam
Diazepam
Flunitrazepam
Flurazepam
Lorazepam
Nordiazepam
Oxazepam
Temazepam
*Reference ranges provided for informational purposes only. See patient report for test interpretation.
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Cocaine | 300 |
Benzodiazepine
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Benzodiazepine | 200 |
Screen Test Name | Cutoff (ng/mL) |
|---|---|
Buprenorphine | 5 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Amphetamine | 500 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Barbiturates | 200 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
ETG | 500 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
ETG | 500 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
EDDP | 100 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Fentanyl | 1 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Methadone | 300 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
PCP | 25 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Opiate | 300 |
Screen Test Name | Screen Test Name Cutoff (ng/mL) |
|---|---|
Oxycodone | 300 |
Screen Test Name | Cutoff (ng/mL) |
|---|---|
Methamphetamine | 500 |
Screen Test Name | Cutoff (ng/mL) |
|---|---|
THC | 50 |
Screen Test Name | Cutoff (ng/mL) |
|---|---|
ETG | 500 |
Amphetamine | 500 |
Barbiturates | 200 |
Benzodiazepine | 200 |
Cotinine | 500 |
Cocaine | 300 |
Methadone | 300 |
Opiate | 300 |
Oxycodone | 300 |
THC | 50 |
Fentanyl | 1 |
Buprenorphine | 5 |
PCP | 25 |
Reference Range
Parameter | Reference Range |
|---|---|
Glucose | Negative |
Bilirubin | Negative |
Ketones | Negative |
Specific Gravity | 1.005 - 1.030 |
Blood | Negative |
pH | 5.0 - 8.0 |
Protein | Negative |
Urobilinogen | 0.0 - 1.0 mg/dL |
Nitrate | Negative |
Leukocyte Esterase | Negative |
Microscopic Evaluation | |
WBC | Negative |
RBC | Negative |
Hylaine Casts | Negative |
All other Parameters | Negative |
Parameter | Reference Range |
|---|---|
Microscopic Evaluation | |
WBC | Negative |
RBC | Negative |
Hylaine Casts | Negative |
All other Parameters | Negative |
Parameter | Reference Range |
|---|---|
Glucose | Negative |
Bilirubin | Negative |
Ketones | Negative |
Specific Gravity | 1.005 - 1.030 |
Blood | Negative |
pH | 5.0 - 8.0 |
Protein | Negative |
Urobilinogen | 0.0 - 1.0 mg/dL |
Nitrate | Negative |
Leukocyte Esterase | Negative |
CBC | Adult Male | Adult Female | Adult Female 10^3/uL | Adult Female % |
|---|---|---|---|---|
WBC
| 3.5-10.5 10³/uL | 3.5-10.5 10³/uL | ||
RBC
| 4.32-5.72 10⁶/uL | 3.9-5.03 10⁶/uL | ||
HGB | 13.5-17.5 g/dL | 12.0-15.5 g/dL | ||
HCT | 38.8-50.0% | 34.9-44.5% | ||
MCV | 81.2-95.1 fL | 81.6-98.3fL | ||
MCH | 27-35 pg | 27-35 pg | ||
MCHC | 31-36 g/dL
| 31-36 g/dL
| ||
RDW | 11.8-15.6% | 11.9-15.5%
| ||
PLT | 150-450 10³/uL | 150-450 10³/uL
| ||
Differential | Adult Male 10³/uL | Adult Male %
| ||
Neutrophils | 1.7-7.0 | 55-70
| 1.7-7.0
| 55-70 |
Lymphocytes | 0.9-2.9 | 20-40
| 0.9-2.9
| 20-40 |
Monocytes | 0.3-0.9 | 2-8
| 0.3-0.9
| 2-8 |
Eosinophils | 0.0-0.5 | 1-4
| 0.0-0.5
| 1-4 |
Basophils | 0.0-0.3 | 0.5-1
| 0-0.3
| 0.5-1 |
Immature Granulocytes | 0-0.5 | <1.0
| 0-0.5 | <1.0 |
CBC | Adult Male | Adult Female |
|---|---|---|
WBC | 3.5-10.5 10³/uL | 3.5-10.5 10³/uL |
RBC | 4.32-5.72 10⁶/uL | 3.9-5.03 10⁶/uL |
HGB | 13.5-17.5 g/dL | 12.0-15.5 g/dL |
HCT | 38.8-50.0 % | 34.9-44.5% |
MCV | 81.2-95.1 fL | 81.6-98.3 fL |
MCH | 27-35 pg | 27-35 pg |
MCHC | 31-36 g/dL | 31-36 g/dL |
RDW | 11.8-15.6 % | 11.9-15.5% |
PLT | 150-450 10³/uL | 150-450 10³/uL |
Test | Adult Male | Adult Female |
|---|---|---|
ESR | 0-10 mm/hr | 0-20 mm/hr |
CBC | Adult Male | Adult Female |
|---|---|---|
HGB | 13.5-17.5 g/dL | 12.0-15.5 g/dL |
HCT | 38.8-50.0% | 34.9-44.5% |
Test | Adult Male | Adult Female |
|---|---|---|
Reticulocyte Count | 0.0216 – 0.0858 10^6/uL | 0.0195 – 0.0755 10^6/uL |
Testing Description
State Reportable Infection
Pediatric Range
Test Code
Benzodiazepine Screen
Performed
Monday – Saturday
Result available within 24-48 hours of receipt in laboratory
NOTE: Specimens are refrigerated (2-8°) for 14 days before disposal
Contacts
Vibra Health Laboratory
1307- A, Allen Dr
Troy, MI 48083
(248) 846-0663
Last Updated
7/20/23 v.1